Mercado mundial de tratamiento de la amiloidosis por transtiretina: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de tratamiento de la amiloidosis con transtiretina

La amiloidosis por transtiretina es el resultado de la transtiretina, que se produce en el hígado y forma dímeros, a los que siguen monómeros. En la polineuropatía amiloide familiar, los síntomas se detectan por primera vez después de que el paciente supera los 30 años de edad, aunque también se puede detectar a principios de los 20 o finales de los 80. Los biomarcadores cardíacos, como el fragmento N-terminal del péptido natriurético cerebral y la troponina, están presentes en concentraciones anormalmente altas en el corazón, lo que conduce a depósitos de amiloide que pueden ser útiles para un diagnóstico posterior de la enfermedad. Los síntomas pueden empeorar si el exceso de proteína amiloide comienza a acumularse en los nervios. Teniendo en cuenta el hecho de que la identificación de los síntomas, el diagnóstico y el tratamiento oportunos son importantes para una recuperación más rápida del paciente.

 Data Bridge Market Research analiza la tasa de crecimiento del mercado global de tratamiento de la amiloidosis por transtiretina en el período de pronóstico 2023-2030. La CAGR esperada del mercado global de tratamiento de la amiloidosis por transtiretina tiende a rondar el 8,1% en el período de pronóstico mencionado. El mercado se valoró en USD 5,10 millones en 2022 y crecerá a USD 9,51 millones para 2030. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de tratamiento de la amiloidosis con transtiretina

Market Definition

Transthyretin amyloidosis is a slowly progressive disease in which abnormal deposits of a protein called amyloid occur in the body's organs and tissues of the person. It is a progressive and fatal rare disease that can destroy nerve cells. It is often considered difficult to recognize and diagnose properly, and treatment is generally critical. However, the most common symptoms include heart failure, chronic diarrhea, weight loss, dry mouth, constipation, carpal tunnel syndrome, impaired kidney function, and floaters.

Global Transthyretin Amyloidosis Treatment Market Dynamics

Drivers

• Increase in the elderly population

The increasing elderly population in the country is expected to increase the incidence of transthyretin amyloidosis during the forecast period. According to the NCBI data, an age-related form of amyloidosis mainly affects the heart and is also known as wild-type ATTR. For instance, in 2020, about 727 million people worldwide were aged 65 years and above. It has been seen that the elderly population worldwide is growing significantly at a rate of 16.0% and is estimated to reach 1.5 billion in 2050. This factor enhances the market growth.

• Robust pipeline for transthyretin amyloidosis therapeutics 

Several market players for the proper diagnosis and treatment of the disease are performing intensive R&D. For instance, in August 2022, Alnylam Pharmaceuticals, Inc. received FDA authorization for the drug Onpattro that could be used for nerve pain treatment caused by hereditary transthyretin amyloidosis. Furthermore, its phase III data shows that it has the potential to help patients suffering from cardiac-related issues for rare protein diseases.

Opportunities

• Increased initiatives by governmental bodies

Several initiatives undertaken by government and non-government bodies to create awareness associated with the disease and its treatment benefits among people are projected to boost early diagnosis of the disease, thus increasing the treatment rate. For instance, in May 2021, the Australian Amyloidosis Network organized a biennial touring workshop to create awareness about the disease among several healthcare professionals and patients with ATTR amyloidosis. The aim was to support the physicians and patients in understanding the disease's complexity, which will further help in developing new therapies for treating transthyretin amyloidosis.

• Increasing demand for targeted therapy

Targeted therapy is projected to witness the fastest growth during the forecast period due to increasing initiatives undertaken by major market players to support patients. For instance, Akcea Therapeutics, Inc. operates a patient assistance program called "Akcea Connect" to support hATTR amyloidosis patients. Under this program, the eligible person and their families get free, private, and personalized support across the U.S. This will increase awareness about available drug therapies, encouraging general practitioners to prescribe these drugs to transthyretin amyloidosis patients.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified healthcare professionals who cannot treat patients with appropriate treatment methods could limit the growth of the global transthyretin amyloidosis treatment market during a forecast period.

• High cost of transthyretin amyloidosis

High costs of recently launched drugs are projected to hinder the market growth. For instance, as per the reports of Alnylam Pharmaceutical, Inc., the cost of Patisiran is about US$ 450,000 annually before insurance. Another drug, Inotersen, which is manufactured by Ionis Pharmaceuticals and in partnership with Akcea Therapeutics, received approval for hereditary Transthyretin Amyloidosis Polyneuropathy indication, and the drug costs US$ 450,000 yearly.  

This global transthyretin amyloidosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global transthyretin amyloidosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Transthyretin Amyloidosis Treatment Market     

The COVID-19 pandemic negatively impacted the market growth due to the decrease in clinical trials for the drugs which could be used for the transthyretin amyloidosis treatment. For instance, in September 2020, a 74% reduction was witnessed in the average number of patients involved in clinical trials. Patients suffering from transthyretin amyloidosis have a higher risk of mortality and morbidity due to age and ATTR- amyloidosis-related organ dysfunction. The consequences of delayed diagnosis and interrupting treatment of patients should be balanced, considering the risk of exposure to the virus in the healthcare setting.

Recent Development

• In July 2019, Health Canada approved ONPATTRO for the treatment of hATTR with polyneuropathy in adults

Global Transthyretin Amyloidosis Treatment Market Scope

The global transthyretin amyloidosis treatment market is segmented on the basis of drug type, disease type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Tafamidis
• Patisiran
• Inotersen
• Others

Diseases Type

• Hereditary Transthyretin Amyloidosis
• Wild Transthyretin Amyloidosis

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Transthyretin Amyloidosis Treatment Market Regional Analysis/Insights

The global transthyretin amyloidosis treatment market is analyzed and market size insights and trends are provided by drug type, disease type, distribution channel and end-user as referenced above.

The major countries covered in the global transthyretin amyloidosis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for the global transthyretin amyloidosis treatment market throughout the forecasted period due to increased new research and developments on the transthyretin amyloidosis treatment market.

North America dominates the market due to the presence of key manufacturers and increasing research and development activities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Transthyretin amyloidosis Treatment Market Share Analysis

El panorama competitivo del mercado global de tratamiento de la amiloidosis por transtiretina proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento del producto, la amplitud y la extensión del producto, el dominio de la aplicación. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en el mercado global de tratamiento de la amiloidosis por transtiretina

Los actores clave que operan en el mercado global de tratamiento de la amiloidosis por transtiretina incluyen:

• Pfizer Inc (Estados Unidos)
• AstraZeneca (Reino Unido)
• Prothena Corporation plc (Irlanda)
• Ionis Pharmaceuticals (Estados Unidos)
• BELLUS Health Inc (Canadá)
• Alnylam Pharmaceuticals, Inc. (Estados Unidos)
• Eidos Therapeutics, Inc. (Estados Unidos)
• SOM BIOTECH (España)
• Abbvie, Inc. (Estados Unidos)
• Bausch Health Companies Inc. (Estados Unidos)
• Compañía Bristol Myers Squibb (Estados Unidos)
• GSK Plc. (Estados Unidos)
• Merck KGaA (Alemania)
• Sanofi (Francia)

SKU-58531